1-butyl-4-(2,3-dichlorophenyl)piperazine | 1383430-54-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: 1-butyl-4-(2,3-dichlorophenyl)piperazine
• CAS: 1383430-54-3
• 化学式: C₁₄H₂₀Cl₂N₂
• 分子量: 287.232
• InChiKey: GXSJLZZVCQCUTH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.4
• 重原子数：
  18
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.57
• 拓扑面积：
  6.5
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  正溴丁烷 、 1-(2,3-二氯苯基)哌嗪 在 potassium carbonate 作用下， 以 丙酮 为溶剂， 以95%的产率得到1-butyl-4-(2,3-dichlorophenyl)piperazine
  参考文献：
  名称：

  Molecular Determinants of Selectivity and Efficacy at the Dopamine D3 Receptor

  摘要：

  The dopamine D3 receptor (D3R) has been implicated in substance abuse and other neuropsychiatric disorders. The high sequence homology between the D3R and D2R, especially within the orthosteric binding site (OBS) that binds dopamine, has made the development of D3R-selective compounds challenging. Here, we deconstruct into pharmacophoric elements a series of D3R-selective substituted-4-phenylpiperazine compounds and use computational simulations and binding and activation studies to dissect the structural bases for D3R selectivity and efficacy. We find that selectivity arises from divergent interactions within a second binding pocket (SBP) separate from the OBS, whereas efficacy depends on the binding mode in the OBS. Our findings reveal structural features of the receptor that are critical to selectivity and efficacy that can be used to design highly D3R-selective ligands with targeted efficacies. These findings are generalizable to other GPCRs in which the SBP can be targeted by bitopic or allosteric ligands.

  DOI：

  10.1021/jm300482h

文献信息

• ARYLPIPERAZINE-CONTAINING PYRROLE 3-CARBOXAMIDE DERIVATIVES FOR TREATING DEPRESSIVE DISORDERS
  申请人：Lee Jinhwa

  公开号：US20110178091A1

  公开（公告）日：2011-07-21

  The present invention relates to novel arylpiperazine-containing pyrrole 3-carboxamide derivatives of formula (I) or a pharmaceutically acceptable salt thereof which is useful for preventing or treating depressive disorders. The present invention also provides a method for preparing the arylpiperazine-containing pyrrole 3-carboxamide derivatives or the pharmaceutically acceptable salt thereof, a pharmaceutical composition containing same, and a method for preventing or treating depressive disorders.

  本发明涉及一种新的芳基哌嗪含有吡咯3-羧酰胺衍生物的化合物（I），或其药学上可接受的盐，用于预防或治疗抑郁症。本发明还提供了制备芳基哌嗪含有吡咯3-羧酰胺衍生物或其药学上可接受的盐的方法，包括含有它们的药物组合物，以及预防或治疗抑郁症的方法。
• PROCESS FOR SYNTHESIZING OXIDIZED LACTAM COMPOUNDS
  申请人：Alkermes Pharma Ireland Limited

  公开号：EP2566329B1

  公开（公告）日：2020-09-09
• Dual function drugs and uses thereof
  申请人：Altar A. Charles

  公开号：US20070142399A1

  公开（公告）日：2007-06-21

  Dual action compounds are provided that are inhibitors of catechol-omethyltransferase (COMT) enzyme and are also partial agonists or antagonists of the D2 receptor, or agonists of the D1 receptor, or interact in these ways with both D1 and D2 receptors. Use of the compounds for treating neuropsychiatric disorders, particularly schizophrenia and mild cognitive impairment, is also described.
• US8895558B2
  申请人：——

  公开号：US8895558B2

  公开（公告）日：2014-11-25
• Molecular Determinants of Selectivity and Efficacy at the Dopamine D3 Receptor
  作者：Amy Hauck Newman、Thijs Beuming、Ashwini K. Banala、Prashant Donthamsetti、Katherine Pongetti、Alex LaBounty、Benjamin Levy、Jianjing Cao、Mayako Michino、Robert R. Luedtke、Jonathan A. Javitch、Lei Shi

  DOI：10.1021/jm300482h

  日期：2012.8.9

  The dopamine D3 receptor (D3R) has been implicated in substance abuse and other neuropsychiatric disorders. The high sequence homology between the D3R and D2R, especially within the orthosteric binding site (OBS) that binds dopamine, has made the development of D3R-selective compounds challenging. Here, we deconstruct into pharmacophoric elements a series of D3R-selective substituted-4-phenylpiperazine compounds and use computational simulations and binding and activation studies to dissect the structural bases for D3R selectivity and efficacy. We find that selectivity arises from divergent interactions within a second binding pocket (SBP) separate from the OBS, whereas efficacy depends on the binding mode in the OBS. Our findings reveal structural features of the receptor that are critical to selectivity and efficacy that can be used to design highly D3R-selective ligands with targeted efficacies. These findings are generalizable to other GPCRs in which the SBP can be targeted by bitopic or allosteric ligands.